OncoSec to Present at Investment Conferences in January

SAN DIEGO, Jan. 3, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that members of its leadership team will be making presentations at two high-profile events in January: 2017 East/West CEO Conference and the 9^th Annual Conference Biotech Showcase.

2017 East/West CEO Conference
OncoSec's CEO, Mr. Punit Dhillon, will participate in a panel discussion, titled "Building a Biotech: Innovative Business Models," at the East/West CEO Conference on January 7, 2017, at 9:30 AM PST in San Francisco. The East/West CEO is a networking forum for industry CEOs, decision makers, and investors in the life sciences. For more information, please visit: http://bbbiotechconference.com/conferences.php.

9^th Annual Conference Biotech Showcase
Mr. Dhillon will present a corporate overview at the Biotech Showcase on January 11, 2017, at 11:30 AM PST, in San Francisco.  This conference provides a forum for biotechnology and life sciences companies to meet with investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. For more information, please visit: https://ebdgroup.knect365.com/biotech-showcase/.

To view the live webcast, please visit http://ir.oncosec.com/events-presentations. An archived version of the webcast will be available for replay on the Company website.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or non-responsive to anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse® IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT:
Punit Dhillon
President and Chief Executive Officer
OncoSec Medical Incorporated
855-662-6732
[email protected]

SOURCE OncoSec Medical Incorporated

Related Links

http://www.oncosec.com